ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Berlin, Germany and Zurich, Switzerland – April 12, 2023
Berlin, Germany and Zurich, Switzerland – April 12, 2023
New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million
Funds will be used to advance clinical pipeline and further build Ariceum Therapeutics
Olivier Litzka…
Be prepared to learn new things constantly
Deadline: May 1st, 2023
BREAKTHROUGH RESEARCH WAS AND IS THE KEY TO UNDERSTANDING AND SOLVING THE GREATEST CHALLENGES OF OUR TIME
“Ultimately, the goal is to bring health-innovations Made in Europe to the marketplace.”
Large-scale study shows that DX-ICD systems together with Home Monitoring allow for reliable guideline-recommended monitoring of subclinical AF
Genes are not the only drivers of evolution. The iconic fins of skates are caused by changes in the non-coding parts of the genome and its three-dimensional structure, a research team including Darío Lupiáñez at the Max Delbrück Center reports in…
Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Jiangsu…
Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225…
Critically ill COVID-19 patients often have antibodies in their blood that bind to the body’s own structures, so-called autoantibodies. Scientists from the BIH at Charité and the Max Delbrück Center have now discovered that these autoantibodies…